Welcome Side Effect: Unpleasant Rash Signifies Better Outcomes For Pancreatic And Lung Cancer Patients
The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug’s developer, OSI Pharmaceuticals, Inc. [click link for full article]